ClinicalTrials.gg

Program

VSA003

A development code.

Its studies are mostly in Homozygous Familial Hypercholesterolemia · Dyslipidemias, led by Visirna Therapeutics HK.

Furthest: phase 3, since Nov 26, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Visirna Therapeutics HK21 open or runningphase 3since Nov 26, 2024Apr 26, 2023none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Apr 26, 2023First study: phase 1 study in DyslipidemiasFirst studyNCT05851066 · 36 enrolled · China
  2. Nov 26, 2024Phase 3 study in Homozygous Familial HypercholesterolemiaNCT06712771 · 46 enrolled · China

TargetBeta

ANGPTL3 →read by rule
“In this clinical study, the efficacy and safety of VSA003, an RNAi-based therapeutic targeting ANGPTL3, will be evaluated in subjects with HoFH.”study text, by rule · the study

Other programs on ANGPTL3

ProgramCompanyFurthest phaseStudies
SHR-1918Jiangsu HengRui Medicinephase 38
EDP167ruleeddingpharm-zhuhai-co-ltdphase 23

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06712771Homozygous Familial Hypercholesterolemia · China3Active, not recruitingDec 31, 202546
NCT05851066Dyslipidemias · China1CompletedMay 7, 202436

How it is read

Names in the registry

  • “VSA003”, 2 entries

Codes read as this program: VSA003.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.